hippuric acid has been researched along with Cirrhosis, Liver in 5 studies
hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591
N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the 7 control subjects, the mean level (+/- SEM) of Cmax for serum benzoate was 104." | 1.28 | Clinical significance of benzoate-metabolizing capacity in patients with chronic liver disease: pharmacokinetic analysis. ( Amisaki, T; Fujii, T; Hasegawa, M; Hoshino, U; Kobayashi, J; Suou, T; Tabuchi, F; Takayama, M; Yamada, S; Yamamoto, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajaj, JS | 1 |
| Cox, IJ | 1 |
| Betrapally, NS | 1 |
| Heuman, DM | 1 |
| Schubert, ML | 1 |
| Ratneswaran, M | 1 |
| Hylemon, PB | 1 |
| White, MB | 1 |
| Daita, K | 1 |
| Noble, NA | 1 |
| Sikaroodi, M | 1 |
| Williams, R | 1 |
| Crossey, MM | 1 |
| Taylor-Robinson, SD | 1 |
| Gillevet, PM | 1 |
| Poo, JL | 1 |
| Cervera, E | 1 |
| de Hoyos, A | 1 |
| Gil, S | 1 |
| Cadena, M | 1 |
| Uribe, M | 1 |
| LYCZEWSKA, J | 1 |
| RAFALOWICZ, A | 1 |
| KONDO, T | 1 |
| KAWARADA, H | 1 |
| YUKITAKE, M | 1 |
| Yamada, S | 1 |
| Yamamoto, T | 1 |
| Suou, T | 1 |
| Fujii, T | 1 |
| Takayama, M | 1 |
| Amisaki, T | 1 |
| Tabuchi, F | 1 |
| Kobayashi, J | 1 |
| Hasegawa, M | 1 |
| Hoshino, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01458990] | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Analysis at baseline will be compared to that at 2 weeks. This will be specifically, changes in those with PPI withdrawal compared to those with PPI initiation (NCT01458990)
Timeframe: 2 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| PPI Initiation | 0 |
| PPI Withdrawal | 0 |
Analysis at baseline will be compared to that at 2 weeks using Multitagged sequencing. Number of patients with overgrowth of oral microbiota in their stool after PPI therapy withdrawal or initiation were specifically analyzed. (NCT01458990)
Timeframe: 2 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| PPI Inititation | 45 |
| PPI Withdrawal | 15 |
1 review available for hippuric acid and Cirrhosis, Liver
| Article | Year |
|---|---|
[Rationale for the use of sodium benzoate in clinical hepatology].
Topics: Acetates; Adult; Animals; Child; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glycine; He | 1990 |
1 trial available for hippuric acid and Cirrhosis, Liver
| Article | Year |
|---|---|
Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.
Topics: Arginine; Biomarkers; Case-Control Studies; Feces; Female; Gastrins; Hippurates; Humans; Intestines; | 2014 |
3 other studies available for hippuric acid and Cirrhosis, Liver
| Article | Year |
|---|---|
[EXCRETION OF HIPPURIC ACID AND BENZOYLGLUCURONIC ACID FOLLOWING SODIUM BENZOATE LOAD IN NORMAL SUBJECTS AND IN LIVER DISEASES].
Topics: Benzoates; Biomedical Research; Glucuronates; Hepatitis; Hepatitis A; Hepatolenticular Degeneration; | 1963 |
[ON THE CLINICAL APPLICATION OF HIPPURIC ACID SYNTHESIS TEST (OGATA'S METHOD)].
Topics: Adolescent; Diabetes Mellitus; Hepatitis; Hippurates; Humans; Hypertension; Jaundice; Liver Cirrhosi | 1964 |
Clinical significance of benzoate-metabolizing capacity in patients with chronic liver disease: pharmacokinetic analysis.
Topics: Adult; Aged; Benzoates; Benzoic Acid; Chronic Disease; Female; Hepatitis; Hippurates; Humans; Liver | 1992 |